Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NexOptic Begins Announcing New Team Additions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Allakos Inc ALLK

Healthcare Biotechnology
Allakos Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALLK)

Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 13, 2023

Allakos Appoints Neil Graham to its Board of Directors

GlobeNewswire August 30, 2023

Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 9, 2023

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

GlobeNewswire August 2, 2023

Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition

GlobeNewswire June 12, 2023

Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023

GlobeNewswire June 5, 2023

Allakos Provides Business Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 9, 2023

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

GlobeNewswire March 6, 2023

Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology

GlobeNewswire November 29, 2022
View More News ››

Opinion & Analysis (NDAQ:ALLK)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALLK)

SHOULD ALLAKOS INC BE ON YOUR INVESTMENT WATCHLIST?

$ALLK  Allakos Inc. (NASDAQ:ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for...
AviseAnalytics - January 10, 2022
View more Bullboard ››

Eloro Resources Ltd

Eloro Resources Ltd

Eloro Resources Ltd. is a Canada-based exploration and mine development company. The Company is engaged in the exploration ...
View More »